Targeting TNF-α and its binding to TNFR has therapeutic potential due to well-established mechanism that activates NF-kB-p50/65 proteins, producing pro-inflammatory cytokines and proteins in RA [4]. This evidence concerns the gene NFKB1 and rheumatoid arthritis.